FI20011206A - A process for the preparation of therapeutically useful tricyclic diazepines - Google Patents

A process for the preparation of therapeutically useful tricyclic diazepines Download PDF

Info

Publication number
FI20011206A
FI20011206A FI20011206A FI20011206A FI20011206A FI 20011206 A FI20011206 A FI 20011206A FI 20011206 A FI20011206 A FI 20011206A FI 20011206 A FI20011206 A FI 20011206A FI 20011206 A FI20011206 A FI 20011206A
Authority
FI
Finland
Prior art keywords
opt
substd
satd
membered aromatic
preparation
Prior art date
Application number
FI20011206A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI113867B (en
Inventor
Jay D Albright
Marvin F Reich
Fuk-Wah Sum
Santos Efren Guillermo Delos
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of FI20011206A publication Critical patent/FI20011206A/en
Application granted granted Critical
Publication of FI113867B publication Critical patent/FI113867B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Tricyclic diazepine derivs. of formula (I) and their pharmaceutically acceptable salts, esters and pro-drugs are new. Y = (CH2)n, CH(1-3 C alkyl) or CO; AB = (CH2)mN(R3) or N(R3)(CH2)m ; n = 0-2; m = 1-2; provided that when Y = (CH2)n and n = 2, m may also be 0, and when n = 0, m may also be 3, provided also that when Y = (CH2)n and n = 2, m is not 2; R3 = COAr; Ar = substd. phenyl; opt. N-substd. indole; or opt. substd. furan, thiophene or pyrrole; D, E, F = C or N, any C atoms being opt. substd.; Z is such that the ring contg. it = opt. substd. fused phenyl; 5-membered aromatic, opt. satd. ring contg. one of O, N and S; 6-membered aromatic, opt. satd. ring contg. one N; 5- or 6-membered aromatic, opt. satd. ring contg. two N; or 5-membered aromatic, opt. satd. ring contg. one N, and either one O or one S; the heterocyclic rings are opt. substd.
FI20011206A 1993-07-29 2001-06-07 A process for the preparation of therapeutically useful pyrrolo [1,2-a] quinoxaline FI113867B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10000493A 1993-07-29 1993-07-29
US10000493 1993-07-29

Publications (2)

Publication Number Publication Date
FI20011206A true FI20011206A (en) 2001-06-07
FI113867B FI113867B (en) 2004-06-30

Family

ID=22277643

Family Applications (3)

Application Number Title Priority Date Filing Date
FI943543A FI110944B (en) 1993-07-29 1994-07-28 Process for the preparation of therapeutically useful pyrrolo, pyrazolo and imidazo [2,1-c] [1,4] diazepines
FI20011207A FI113868B (en) 1993-07-29 2001-06-07 Tri:cyclic diazepine derivs. - act as non-peptide vasopressin and oxytocin antagonists, used to treat e.g. congestive heart failure and liver cirrhosis
FI20011206A FI113867B (en) 1993-07-29 2001-06-07 A process for the preparation of therapeutically useful pyrrolo [1,2-a] quinoxaline

Family Applications Before (2)

Application Number Title Priority Date Filing Date
FI943543A FI110944B (en) 1993-07-29 1994-07-28 Process for the preparation of therapeutically useful pyrrolo, pyrazolo and imidazo [2,1-c] [1,4] diazepines
FI20011207A FI113868B (en) 1993-07-29 2001-06-07 Tri:cyclic diazepine derivs. - act as non-peptide vasopressin and oxytocin antagonists, used to treat e.g. congestive heart failure and liver cirrhosis

Country Status (29)

Country Link
US (2) US5516774A (en)
EP (1) EP0636625B1 (en)
JP (1) JP3782475B2 (en)
KR (1) KR100347479B1 (en)
CN (2) CN1039908C (en)
AT (1) ATE176234T1 (en)
AU (1) AU683660B2 (en)
BR (1) BR1100563A (en)
CA (1) CA2128956C (en)
CZ (1) CZ291322B6 (en)
DE (1) DE69416211T2 (en)
DK (1) DK0636625T3 (en)
EC (1) ECSP941137A (en)
ES (1) ES2129090T3 (en)
FI (3) FI110944B (en)
GR (1) GR3030069T3 (en)
HK (1) HK1011363A1 (en)
HU (1) HU220707B1 (en)
IL (1) IL110435A (en)
LV (1) LV12497B (en)
NO (1) NO301827B1 (en)
NZ (1) NZ264115A (en)
PE (1) PE17895A1 (en)
PH (1) PH31469A (en)
PL (1) PL178563B1 (en)
RU (1) RU2126006C1 (en)
SG (1) SG47522A1 (en)
SK (1) SK280836B6 (en)
ZA (1) ZA945603B (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968930A (en) * 1993-07-29 1999-10-19 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5889001A (en) * 1993-07-29 1999-03-30 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5733905A (en) * 1993-07-29 1998-03-31 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5521173A (en) * 1995-01-17 1996-05-28 American Home Products Corporation Tricyclic benzazepine vasopressin antagonists
US5536718A (en) * 1995-01-17 1996-07-16 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5753648A (en) * 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
AR002459A1 (en) * 1995-01-17 1998-03-25 American Cyanamid Co TRASCINIC BENZACEPINE VASOPRESIN ANTAGONISTS, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM, A METHOD FOR TREATING DISEASES AND A PROCEDURE FOR THEIR PREPARATION.
US5756497A (en) * 1996-03-01 1998-05-26 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
HUP9904514A3 (en) * 1996-11-01 2000-10-30 Wyeth Corp 5h-pyrrolo[2,1-c][1,4]-benzodiazepin 3-carboxamide derivatives, process for their preparation, their use and pharmaceutical compositions containing them
US5880122A (en) * 1996-11-01 1999-03-09 American Home Products Corporation 3-Carboxamide derivatives of 5H-pyrrolo 2,1-c! 1,4!-benzodiazepines
AUPO395396A0 (en) * 1996-12-02 1997-01-02 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
US6511974B1 (en) 1997-07-30 2003-01-28 Wyeth Tricyclic vasopressin agonists
KR100580805B1 (en) * 1997-07-30 2006-05-17 와이어쓰 Tricyclic compounds having vasopressin agonists activity, their preparations and pharmaceutical compositions comprising them
US6194407B1 (en) 1997-07-30 2001-02-27 American Home Products Corporation Tricyclic pyrido vasopressin agonists
AR018818A1 (en) * 1998-04-03 2001-12-12 Yamano Masaki A PHARMACEUTICAL COMPOSITION FOR THE THERAPY OF AN EDEMA.
US6090803A (en) * 1998-07-24 2000-07-18 American Home Products Corporation Tricyclic vasopressin agonists
US7138393B2 (en) * 1998-07-24 2006-11-21 Wyeth Biologically active vasopressin agonist metabolites
ATE249465T1 (en) 1999-01-19 2003-09-15 Ortho Mcneil Pharm Inc TRICYCLIC BENZODIAZEPINES AS VASOPRESSIN ANTAGONISTS
US6344451B1 (en) 1999-02-04 2002-02-05 American Home Products Pyrrolobenzodiazepine carboxyamide vasopressin agonists
US6297234B1 (en) 1999-02-04 2001-10-02 American Home Products Corporation Arylthiophene vasopressin agonists
US6235900B1 (en) 1999-02-04 2001-05-22 American Home Products Corporation Tricyclic pyridine N-oxides vasopressin agonists
US6620807B1 (en) 1999-02-04 2003-09-16 Wyeth Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists
CA2358892A1 (en) * 1999-02-04 2000-08-10 Robert John Steffan Pyrrolobenzodiazepine carboxyamide vasopressin agonists
US6352718B1 (en) 1999-09-27 2002-03-05 American Cyanamid Company Vasopressin antagonist formulation and process
US6420358B1 (en) 1999-09-27 2002-07-16 American Cyanamid Company Vasopressin antagonist and diuretic combination
US6437006B1 (en) 1999-09-27 2002-08-20 American Cyanamid Company Pharmaceutical carrier formulation
EA200200414A1 (en) * 1999-09-27 2002-12-26 Американ Цианамид Компани COMPOSITION OF ANTAGONIST VAZOPRESSIN AND METHOD FOR ITS OBTAINING
GB0000079D0 (en) 2000-01-05 2000-02-23 Ferring Bv Novel antidiuretic agents
BR0110428A (en) * 2000-04-28 2003-06-17 Sankyo Co A compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition, uses of a compound or a pharmacologically acceptable salt thereof, a gamma modulator and a partial antagonist, agents that inhibit adipocyte differentiation, which enhances or restores osteogenic function, for the treatment or prevention of osteoporosis, which has ppar gamma modulating, blood sugar lowering activity, for the treatment or prevention of diabetes mellitus, and for the treatment or prevention
GB0015601D0 (en) 2000-06-26 2000-08-16 Ferring Bv Novel antidiuretic agents
US7064120B2 (en) * 2001-04-12 2006-06-20 Wyeth Tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
US7022699B2 (en) 2001-04-12 2006-04-04 Wyeth Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
US6903091B2 (en) * 2001-04-12 2005-06-07 Wyeth Biphenyl vasopressin agonists
US6900200B2 (en) 2001-04-12 2005-05-31 Wyeth Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
US7202239B2 (en) * 2001-04-12 2007-04-10 Wyeth Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists
US7109193B2 (en) * 2001-04-12 2006-09-19 Wyeth Tricyclic diazepines tocolytic oxytocin receptor antagonists
ATE375346T1 (en) * 2001-04-12 2007-10-15 Wyeth Corp CYCLOHEXYLPHENYL VASOPRESSIN AGONISTS
US6977254B2 (en) * 2001-04-12 2005-12-20 Wyeth Hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
US7326700B2 (en) * 2001-04-12 2008-02-05 Wyeth Cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
WO2003035602A1 (en) * 2001-10-25 2003-05-01 Sankyo Company, Limited Lipid modulators
US7414052B2 (en) * 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
GB0412874D0 (en) * 2004-06-09 2004-07-14 Pfizer Ltd Novel pharmaceuticals
EP1632494A1 (en) * 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
EP2113178A1 (en) 2008-04-30 2009-11-04 Philip Morris Products S.A. An electrically heated smoking system having a liquid storage portion
US8420633B2 (en) * 2010-03-31 2013-04-16 Hoffmann-La Roche Inc. Aryl-cyclohexyl-tetraazabenzo[e]azulenes
US8461151B2 (en) * 2010-04-13 2013-06-11 Hoffmann-La Roche Inc. Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes
US8492376B2 (en) * 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8481528B2 (en) * 2010-04-26 2013-07-09 Hoffmann-La Roche Inc. Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes
PL2587919T3 (en) * 2010-07-01 2018-05-30 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
AR084070A1 (en) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc BROMODOMINIUM INHIBITORS AND USES OF THE SAME
US8903228B2 (en) 2011-03-09 2014-12-02 Chong Corporation Vapor delivery devices and methods
US9399110B2 (en) 2011-03-09 2016-07-26 Chong Corporation Medicant delivery system
MX356624B (en) 2011-03-09 2018-06-06 Chong Corp Medicant delivery system.
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9328117B2 (en) 2011-06-17 2016-05-03 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
CN107259647B (en) 2011-09-06 2020-03-20 英美烟草(投资)有限公司 Heating smokable material
KR101953201B1 (en) 2011-09-06 2019-02-28 브리티시 아메리칸 토바코 (인베스트먼츠) 리미티드 Heating smokeable material
CN103288829A (en) * 2012-02-24 2013-09-11 中国科学院大连化学物理研究所 Method for synthesizing chiral dihydro-5H-pyrrolo[2,1-c][1,4]-benzodiazepino-5-one
GB201207039D0 (en) 2012-04-23 2012-06-06 British American Tobacco Co Heating smokeable material
TWI602820B (en) 2012-06-06 2017-10-21 星宿藥物公司 Bromodomain inhibitors and uses thereof
US9624244B2 (en) 2012-06-06 2017-04-18 Constellation Pharmaceuticals, Inc. Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
WO2013191041A1 (en) * 2012-06-22 2013-12-27 住友化学株式会社 Amide compound and use thereof for pest control
EP2765128A1 (en) * 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
CN103755707B (en) * 2013-09-17 2015-11-18 天津药物研究院 Lixivaptan crystal form II and its production and use
CN104059070B (en) * 2013-09-17 2016-02-10 天津药物研究院有限公司 Lixivaptan crystalline form I and its production and use
CN103694240B (en) * 2013-09-18 2015-11-18 天津药物研究院 Solvate of lixivaptan and its production and use
CN106687463B (en) 2014-06-20 2019-04-09 星座制药公司 A kind of crystal form of acetamides
CN104140429B (en) * 2014-07-25 2015-11-18 天津药物研究院 Lixivaptan crystalline form V and its production and use
CN104710429B (en) * 2015-02-04 2017-02-22 浙江大学 Method for chiral spirocyclic phosphoric acid catalyzed synthesis of optically active quinoxaline derivative
US11924930B2 (en) 2015-08-31 2024-03-05 Nicoventures Trading Limited Article for use with apparatus for heating smokable material
US20170055584A1 (en) 2015-08-31 2017-03-02 British American Tobacco (Investments) Limited Article for use with apparatus for heating smokable material
US20170119046A1 (en) 2015-10-30 2017-05-04 British American Tobacco (Investments) Limited Apparatus for Heating Smokable Material
BR112018010216B1 (en) 2015-11-20 2024-02-15 Forma Therapeutics, Inc PURINONES AS INHIBITORS OF UBIQUITIN 1 SPECIFIC PROTEASE AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS
CA3065910A1 (en) * 2017-06-09 2018-12-13 Palladio Biosciences, Inc. Formulations of lixivaptan for the treatment of polycystic disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3860600A (en) * 1972-07-10 1975-01-14 Sterling Drug Inc Octahydropyrrido{8 2,1-c{9 {8 1,4{9 benzodiazepines
DE69009785T2 (en) * 1989-02-10 1994-11-03 Otsuka Pharma Co Ltd Carbostyril derivatives.
EP0450097B1 (en) * 1989-10-20 1996-04-24 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
TW199153B (en) * 1990-08-07 1993-02-01 Dtsuka Seiyaku Kk
TW198715B (en) * 1991-04-19 1993-01-21 Dtsuka Seiyaku Kk
EP0533242A3 (en) * 1991-09-16 1993-09-15 Merck & Co. Inc. Substituted derivatives of piperazinylcamphorsulfonyl oxytocin antagonists
DE69223573D1 (en) * 1991-09-16 1998-01-29 Merck & Co Inc Hydantoin and succinimide substituted spiroindanylcamphorsulfonyl as oxytocin antagonists
US5204349A (en) * 1991-09-16 1993-04-20 Merck & Co., Inc. Amide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists
EP0533240A3 (en) * 1991-09-16 1993-09-29 Merck & Co. Inc. Substituted amine derivatives of piperazinylcamphorsulfonyl oxytocin antagonists

Also Published As

Publication number Publication date
US5624923A (en) 1997-04-29
PL304498A1 (en) 1995-02-06
ZA945603B (en) 1995-03-09
LV12497B (en) 2000-09-20
BR1100563A (en) 2000-02-08
HU9402219D0 (en) 1994-09-28
LV12497A (en) 2000-06-20
EP0636625B1 (en) 1999-01-27
FI943543A0 (en) 1994-07-28
EP0636625A2 (en) 1995-02-01
CZ291322B6 (en) 2003-02-12
RU94027583A (en) 1996-07-20
FI110944B (en) 2003-04-30
HU220707B1 (en) 2002-04-29
ATE176234T1 (en) 1999-02-15
FI113868B (en) 2004-06-30
EP0636625A3 (en) 1995-05-17
KR950003295A (en) 1995-02-16
ES2129090T3 (en) 1999-06-01
PH31469A (en) 1998-11-03
CN1205335A (en) 1999-01-20
CN1039908C (en) 1998-09-23
JPH07157486A (en) 1995-06-20
FI113867B (en) 2004-06-30
PE17895A1 (en) 1995-07-18
HK1011363A1 (en) 1999-07-09
IL110435A (en) 2003-11-23
DK0636625T3 (en) 1999-09-13
CA2128956C (en) 2004-10-05
SK280836B6 (en) 2000-08-14
CZ179994A3 (en) 1995-02-15
HUT71495A (en) 1995-11-28
AU6877794A (en) 1995-02-09
SG47522A1 (en) 1998-04-17
GR3030069T3 (en) 1999-07-30
NO301827B1 (en) 1997-12-15
IL110435A0 (en) 1994-10-21
ECSP941137A (en) 1995-02-27
JP3782475B2 (en) 2006-06-07
RU2126006C1 (en) 1999-02-10
KR100347479B1 (en) 2002-12-06
CN1106812A (en) 1995-08-16
DE69416211D1 (en) 1999-03-11
FI20011207A (en) 2001-06-07
PL178563B1 (en) 2000-05-31
AU683660B2 (en) 1997-11-20
NO942816D0 (en) 1994-07-28
CN1056374C (en) 2000-09-13
DE69416211T2 (en) 1999-09-02
NO942816L (en) 1995-01-30
CA2128956A1 (en) 1995-01-30
NZ264115A (en) 1997-10-24
US5516774A (en) 1996-05-14
FI943543A (en) 1995-01-30
SK88194A3 (en) 1995-04-12

Similar Documents

Publication Publication Date Title
FI20011206A (en) A process for the preparation of therapeutically useful tricyclic diazepines
NO931151D0 (en) PROCEDURE FOR THE PREPARATION OF NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS WITH CONDENSED RINGS
IE42410L (en) Olefinic derivatives of aminoacids.
HUT66011A (en) Process for producing 5-heteroarylindole derivatives and pharmaceutical preparations containing them
IE902182L (en) Tricyclic compounds; pharmaceutical compositions
FI962043A0 (en) Substituted 5-ring heterocycles, process for making and using them
DK0600669T3 (en) Photoreactive material
DK160098C (en) TRICYCLIC OXINDOLCARBOXAMIDE DERIVATIVES
ES2141096T3 (en) CEPHALOSPORIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF.
DE69120572D1 (en) Carbapenem derivatives, substituted in the 2-position with substituted pyrrolidinylthio groups
KR950700225A (en) Benzodiazepine derivatives useful as CCK-receptor antagonists (BENZODIAZEPIN DERIVATIVES USEFUL AS CCK-RECEPTOR ANTAGONISTS)
ES2063157T3 (en) NEW DERIVATIVES OF INDOL, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
ZA892155B (en) Heterocyclic substituted 5,7-dihydropyrrolo(3,2-f)-benzoxazol-6-ones
ES2115178T3 (en) DERIVATIVES OF INDANOTRIONAS AND HYDRAZIDES AND THEIR THERAPEUTIC APPLICATION.

Legal Events

Date Code Title Description
MM Patent lapsed